These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6532540)

  • 1. 2-Methyl-9-hydroxyellipticinium acetate (ellipticinium) in the treatment of lymphomas. Preliminary results of a phase II study.
    Tura S; Mandelli F; Mazza P; Cimino G; Anselmo AP; Amadori S
    Chemioterapia; 1984 Apr; 3(2):79-82. PubMed ID: 6532540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of elliptinium (2-N-methyl-9-hydroxyellipticinium).
    Einzig AI; Gralla RJ; Leyland-Jones BR; Kelsen DP; Cibas I; Lewis E; Greenberg E
    Cancer Invest; 1985; 3(3):235-41. PubMed ID: 4005651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of elliptinium in advanced renal cell carcinoma.
    Caillé P; Mondesir JM; Droz JP; Kerbrat P; Goodman A; Ducret JP; Theodore C; Spielman M; Rouëssé J; Amiel JL
    Cancer Treat Rep; 1985; 69(7-8):901-2. PubMed ID: 4016798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of elliptinium in advanced renal cell carcinoma and carcinoma of the breast.
    Sternberg CN; Yagoda A; Casper E; Scoppetuolo M; Scher HI
    Anticancer Res; 1985; 5(4):415-7. PubMed ID: 4037737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Failure of elliptinium acetate in the treatment of unresectable hepatocarcinoma (phase II trial)].
    Rougier P; Ychou M; Droz JP
    Bull Cancer; 1988; 75(10):979-81. PubMed ID: 2851337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phase I-II studies of a new antineoplastic agent, 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA)].
    Horikoshi N; Ogawa M; Inagaki J; Ezaki K; Inoue K; Okabe K; Nagata T; Aiba K; Domyo M
    Gan To Kagaku Ryoho; 1982 Feb; 9(2):244-9. PubMed ID: 6897858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II. Trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in the treatment of advanced non-Hodgkin's lymphoma.
    Warrell RP; Straus DJ; Young CW
    Cancer Treat Rep; 1980; 64(10-11):1157-8. PubMed ID: 6893952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of elliptinium in advanced breast cancer.
    Rouësse JG; Le Chevalier T; Caille P; Mondesir JM; Sancho-Garnier H; May-Levin F; Spielmann M; De Jager R; Amiel JL
    Cancer Treat Rep; 1985 Jun; 69(6):707-8. PubMed ID: 4016774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of maytansine in patients with advanced lymphomas: an Eastern Cooperative Oncology Group pilot study.
    Rosenthal S; Harris DT; Horton J; Glick JH
    Cancer Treat Rep; 1980; 64(10-11):1115-7. PubMed ID: 7459897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elliptinium acetate in metastatic breast cancer--a phase II study.
    Buzdar AU; Hortobagyi GN; Esparza LT; Holmes FA; Ro JS; Fraschini G; Lichtiger B
    Oncology; 1990; 47(2):101-4. PubMed ID: 2314820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group.
    Hiddemann W; Unterhalt M; Pott C; Wörmann B; Sandford D; Freund M; Engert A; Gassmann W; Holtkamp W; Seufert J
    Semin Oncol; 1993 Oct; 20(5 Suppl 7):28-31. PubMed ID: 8235693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity, pharmacology, and toxicity of ellipticines, ellipticinium, and 9-hydroxy derivatives: preliminary clinical trials of 2-methyl-9-hydroxy ellipticinium (NSC 264-137).
    Paoletti C; Le Pecq JB; Dat-Xuong N; Juret P; Garnier H; Amiel JL; Rouesse J
    Recent Results Cancer Res; 1980; 74():107-23. PubMed ID: 7003658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.
    Borchmann P; Morschhauser F; Parry A; Schnell R; Harousseau JL; Gisselbrecht C; Rudolph C; Wilhelm M; Günther H; Pfreundschuh DM; Camboni G; Engert A
    Haematologica; 2003 Aug; 88(8):888-94. PubMed ID: 12935976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
    Casasnovas RO; Haioun C; Dumontet C; Gabarre J; Richard B; Lederlin P; Caillot D; Stamatoullas A; Morel P; Quesnel B; Blay JY; Bouabdallah K; Gisselbrecht C
    Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A phase II study of mitoxantrone in malignant lymphoma].
    Ibuka T; Sasaki T; Imai K; Sakai Y
    Gan To Kagaku Ryoho; 1986 Aug; 13(8):2612-7. PubMed ID: 3740861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of 9-hydroxy-2-methyl-ellipticinium acetate (ellipticinium) in patients with advanced carcinoma of the lung. EORTC Lung Cancer Cooperative Group.
    Anderson G; Clavel M; Smyth J; Giaccone G; Gracia M; Planting AS; Dalesio O; Kirkpatrick A; McVie G
    Eur J Cancer Clin Oncol; 1989 May; 25(5):909-10. PubMed ID: 2737223
    [No Abstract]   [Full Text] [Related]  

  • 18. [N-Methyl-9 hydroxy-ellipticine (NSC 264-137) in the treatment of malignant metastases. Preliminary results (author's transl)].
    Rouesse J; Tursz T; Le Chevalier T; Huertas D; Amiel JL; Brule G; Callet B; Droz JP; Voisin PM; Sancho-Garnier H; Le Pecq JB; Paoletti C
    Nouv Presse Med; 1981 May; 10(24):1997-9. PubMed ID: 7255136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's lymphoma: a Wisconsin Oncology Network Study.
    Kahl BS; Bailey HH; Smith EP; Turman N; Smith J; Werndli J; Williams EC; Longo WL; Kim KM; McGovern J; Jumonville A
    Cancer Invest; 2005; 23(1):13-8. PubMed ID: 15779863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phase II study of VP-16 (capsule) in malignant lymphomas. A cooperative study].
    Sampi K; Ogawa M; Maekawa T; Takaku F; Kuraishi Y; Ota K; Hirano M; Hoshino A; Shirakawa S; Kimura I
    Gan To Kagaku Ryoho; 1985 Feb; 12(2):314-9. PubMed ID: 3970554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.